Highlighting the role of comprehensive genomic profiling in cancer treatment at ESMO 2024

Highlighting the role of CGP in cancer treatment at ESMO 2024 — Representatives from Illumina gather at their booth during ESMO 2024. | Photo: Mike Rowland

September 16, 2024

🖨 View this article as a printable PDF
🔈 Listen to this article read aloud

At the annual European Society for Medical Oncology (ESMO) congress in Barcelona, Spain, Illumina brought together oncologists, patient advisory groups, clinicians, and researchers to discuss the growing evidence on the benefits of comprehensive genomic profiling (CGP) using liquid biopsy, and how it can help to inform therapy decisions and improve patient care.

This revolutionary technique uses a blood test to detect circulating tumor DNA, which is then sequenced to assess multiple biomarkers in numerous tumor types using a single next-generation sequencing assay. This process is less invasive for patients, requiring a one-time test rather than multiple biopsies, which can add to the patient’s discomfort and prolong the wait for a diagnosis.

Illumina hosted a symposium on liquid-biopsy-based biomarkers during the conference. Professor Umberto Malapelle from the University of Naples highlighted the value of liquid biopsy testing in oncology. Magda Meissner from the QuicDNA project in Wales offered a clear example of the value of government-funded testing in non-small-cell lung cancer using liquid biopsy CGP. Åslaug Helland from the IMPRESS Norway project spoke about the promise of CGP in the treatment of advanced cancer, and Stephen Rowley shared his experience living with colorectal cancer and why he continues to advocate for patients and their families after finishing treatment. ◆

Video: Highlighting the role of CGP in cancer treatment at ESMO 2024

Genomics experts from Italy, Norway, and Wales joined an Illumina-hosted panel on liquid biopsy

September 16, 2024

Recent Articles

For every lab, everywhere

NextSeq 1000 and NextSeq 2000 Reagents

NGS Workflow Finder

DRAGEN v4.3 now available on-premises and on-cloud

Illumina Proactive Instrument Performance Service

Do more, faster than ever

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

Video: Highlighting the role of CGP in cancer treatment at ESMO 2024

Genomics experts from Italy, Norway, and Wales joined an Illumina-hosted panel on liquid biopsy

September 16, 2024

Recent Articles

Share